DATA GRAPHICS | Data Byte
The expanding pipeline of VEGF multispecifics
At least 35 VEGF multispecific programs are in development
April 8, 2025 8:46 PM UTC
The promise of multispecific constructs to improve the therapeutic index of VEGF, while adding to its efficacy via additional targets, has breathed new life into the long-time cancer target.
As the industry awaits global Phase III data from the leading bispecific antibody against PD-1 and VEGF — ivonescimab from Akeso Inc. (HKEX:9926) and Summit Therapeutics Inc. (NASDAQ:SMMT) — the pipeline of multispecifics pairing the angiogenesis target with other therapeutic mechanisms continues to grow...